1-(6-Oxooctyl)pyrrole-2,5-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(6-Oxooctyl)pyrrole-2,5-dione
• 英文别名: 1-(6-oxooctyl)pyrrole-2,5-dione
• 化学式: C₁₂H₁₇NO₃
• 分子量: 223.27
• InChiKey: MURRWSHLLREBEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  54.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20170355769A1

  公开（公告）日：2017-12-14

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  这项发明涉及B7同源物3蛋白（B7-H3）抗体和抗体药物结合物（ADCs），包括使用所述抗体和ADCs的组合物和方法。
• [EN] TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS INHIBITEUR DE TGFBETAR2-ANTICORPS ANTI-LRRC15 ET LEURS UTILISATIONS
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2021102332A1

  公开（公告）日：2021-05-27

  Conjugates comprising a TGFβR2 inhibitor and an anti-LRRC15 antibody, compositions comprising the conjugates, and use of the conjugates in the treatment of disease, such as fibrosis and cancer, are disclosed herein. Also disclosed herein are anti-LRRC15 antibodies, including humanized anti-LRRC15 antibodies.

  本文披露了包括TGFβR2抑制剂和抗LRRC15抗体在内的共轭物，包括这些共轭物的组合物，以及在治疗疾病（如纤维化和癌症）中使用这些共轭物的方法。本文还披露了抗LRRC15抗体，包括人源化的抗LRRC15抗体。
• IMMUNE RESPONSE MODIFIER CONJUGATES
  申请人：3M INNOVATIVE PROPERTIES COMPANY

  公开号：US20150141625A1

  公开（公告）日：2015-05-21

  The present invention provides IRM conjugates that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety in which the covalent link does not depend on UV irradiation.

  本发明提供包括IRM基团和第二活性基团的IRM偶联物，所述第二活性基团与IRM基团共价连接，且共价连接不依赖于紫外辐射。
• CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF
  申请人：Pfizer Inc.

  公开号：EP3327027A1

  公开（公告）日：2018-05-30

  The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.

  本发明涉及细胞毒性五肽、其抗体药物共轭物以及用其治疗癌症的方法。
• LONG-ACTING COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS
  申请人：Apellis Pharmaceuticals, Inc.

  公开号：EP3929206A1

  公开（公告）日：2021-12-29

  In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

  在某些方面，本发明提供了细胞反应性复合素类似物和包含细胞反应性复合素类似物的组合物。在某些方面，本发明进一步提供了使用细胞反应性复合司他丁类似物的方法，例如，治疗补体介导的疾病，例如，抑制补体介导的对细胞、组织或器官的损伤。在某些方面，本发明提供了长效络合素类似物和包含长效络合素类似物的组合物。在某些方面，本发明进一步提供了使用长效复合司他丁类似物的方法，例如，治疗补体介导的疾病，例如，抑制补体介导的对细胞、组织或器官的损伤。在某些方面，本发明提供了靶向康司他丁类似物和包含靶向康司他丁类似物的组合物。在一些方面，本发明进一步提供了使用靶向compstatin类似物的方法，例如，治疗补体介导的疾病，例如，抑制补体介导的对细胞、组织或器官的损伤。